Melanoma associated with TNFa inhibitor agents in the FDA Adverse Event Reporting System (FAERS): Analysis of reported outcomes - 09/05/15
Beatrice Nardone, MD, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; Tanya Bhattacharya, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; Finola M. Bruins, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; Josh A. Hammel, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; Isabel M. Haugh, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; Dennis P. West, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
Le texte complet de cet article est disponible en PDF. Commercial support: None identified. |
Vol 72 - N° 5S1
P. AB209 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?